FDA names chief scientist Bumpus as Woodcock’s successor
FDA launches probe of malignancies linked to CAR-T therapies
FDA kicks off review of Karuna’s schizophrenia drug KarXT
Lilly puts potential $660M on the line for protein-protein interaction blockers
*please scroll down for all the latest news*
